Ceritinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Ceritinib production plant. It encompasses all critical aspects necessary for Ceritinib production, including the cost of Ceritinib production, Ceritinib plant cost, Ceritinib production costs, and the overall Ceritinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ceritinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ceritinib is a targeted cancer therapy primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific genetic mutations. It is indicated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients whose cancer is positive for anaplastic lymphoma kinase (ALK) mutations. It works by inhibiting a protein called anaplastic lymphoma kinase (ALK), which plays a major role in the growth and spread of cancer cells. It is primarily used in patients whose cancer has progressed after other treatments or in those who are resistant to other ALK inhibitors, such as crizotinib. It is also used in combination with other drugs to enhance its effectiveness, improving patient outcomes in cases of advanced cancer. It is often used as a reference compound in clinical trials for potential use in treating other types of cancers that involve ALK mutations.

The market for Ceritinib is driven by its application as an important part of targeted cancer therapies for patients with specific genetic mutations, which promotes its demand in the medical sector. Its application for the treatment of adults with ALK-positive metastatic non-small cell lung cancer (NSCLC) also fuels its demand in the medical and pharmaceutical industries. Its usage as a medication, particularly in patients whose cancer has progressed or are intolerant to crizotinib, also boosts its demand in the medical and healthcare sectors.

Its usage in ongoing research studies to explore its potential applications in other cancers that involve ALK mutations also contributes to its demand in the medical research and biotechnology industries. Industrial Ceritinib procurement is shaped by multiple factors, including the cost and availability of key intermediates, adherence to regulatory protocols for oncology drugs, and patent protection. The role of production innovation, supplier consistency, GMP compliance, and efficient cold-chain logistics further impacts procurement. Growing investment in cancer research, coupled with expanding access to advanced treatments in emerging markets, also supports the market for Ceritinib.

Raw Material for Ceritinib Production

According to the Ceritinib production plant project report, the major raw materials for Ceritinib production include Fluoronitrobenzene, 2-chloro-4-fluorotoluene, and 2,4,5-trichloropyrimidine.

Production Process of Ceritinib

The extensive Ceritinib production cost report consists of the following industrial production process:

1. Production via Amination Reaction: The production process of Ceritinib begins with the preparation of two key aniline intermediates through independent multi-step syntheses. First, 2-(isopropylsulfonyl)aniline is synthesised in three steps starting from fluoronitrobenzene, which involves nitro group manipulation and isopropylsulfonyl installation. In the second step, 2-isopropoxy-5-methyl-4-(piperidin-4-yl)aniline is prepared in four steps from 2-chloro-4-fluorotoluene, which shows piperidine attachment. Then, these intermediates undergo two sequential nucleophilic amination reactions with 2,4,5-trichloropyrimidine, which replaces the chlorines one by one to form Ceritinib as the final product.

Ceritinib is an orally bioavailable anaplastic lymphoma kinase inhibitor that appears as a white to almost white or light yellow powder. The molecular formula of the compound is C28H36ClN5O3S, and its molecular weight is 558.14 g/mol. Its density is 1.3 g/cm³, and it exhibits poor aqueous solubility but is highly bound to plasma proteins at approximately 97 per cent. The compound has a boiling point of approximately 721 degree Celsius at atmospheric pressure and a flash point of approximately 390 degree Celsius. The compound may cause some side effects, which include gastrointestinal toxicity such as diarrhoea, nausea, and vomiting, along with elevated liver enzymes, abdominal pain, and fatigue. Serious adverse effects may include hepatotoxicity, interstitial lung disease, QT interval prolongation, hyperglycemia, bradycardia, and pancreatitis. It is recommended that patients should undergo regular monitoring of liver function tests, lipase and amylase levels, fasting glucose, blood pressure, heart rate, and ECGs while handling the medication.